Carocell Bio Revenue
Biotechnology Research • 
London, England, United Kingdom • 1-10 Employees
Carocell Bio revenue & valuation
| Annual revenue | $598,885 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | No funding |
Key Contacts at Carocell Bio
Graham Combe
Director Of Business Development
Ashley George
Chairman, Non-Executive Director & Interim Chief Financial Officer
Mike Davies
Founder And Chief Executive Officer
David Black
Marketing Director
Company overview
| Headquarters | London Bioscience Innovation Centre (LBIC), 2 Royal College Street, London, England NW1 0NH, GB |
| Phone number | +442081448161 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Life Sciences, Biotechnology, Nanotechnology, Investment, Innovation, Inflammation, Atopic Dermatitis, Inflammatory Bowel Disease, Dermal Scarring, Peptide Innovation |
| Founded | 2018 |
| Employees | 1-10 |
| Socials |
Carocell Bio Email Formats
Carocell Bio uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@carocellbio.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@carocellbio.com | 66.7% |
{first initial}.{last name} | j.doe@carocellbio.com | 33.3% |
About Carocell Bio
Carocell Bio is revolutionising the treatment of skin-related inflammatory conditions with its peptide-based, next-generation approach to promoting healthier skin. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options to patients. This includes treating and preventing AD (eczema) and delaying skin ageing – a process strongly associated with inflammation. Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options to patients. This includes treating and preventing AD (eczema) and delaying skin ageing – a process strongly associated with inflammation. Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Carocell Bio has 3 employees across 2 departments.
Departments
Number of employees
Carocell Bio Tech Stack
Discover the technologies and tools that power Carocell Bio's digital infrastructure, from frameworks to analytics platforms.
Hosting
JavaScript libraries
Maps
Page builders
Analytics
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
India
Australia
Germany
United States
IsraelFrequently asked questions
4.8
40,000 users
